Risk-sharing in the Pharmaceutical Industry The Case of Out-licensing /
The costs of developing a new drug have reached record levels in the pharmaceutical industry. As any failure of a new drug candidate can lead to significant losses, many pharmaceutical companies are looking for new approaches to reduce their exposure to R&D risks. In this context, the book deals...
Saved in:
| Príomhúdar: | |
|---|---|
| Údar Corparáideach: | |
| Formáid: | Leictreonach ríomhLeabhar |
| Teanga: | English |
| Foilsithe: |
Heidelberg :
Physica-Verlag HD : Imprint: Physica,
2006.
|
| Eagrán: | 1st ed. 2006. |
| Sraith: | Contributions to Management Science,
|
| Ábhair: | |
| Rochtain Ar Líne: | https://doi.org/10.1007/3-7908-1668-X |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|
Clár Ábhair:
- Key Issues in Managing Pharmaceutical Innovation
- Risk-sharing as New Paradigm in Pharma R&D Collaborations
- Case Studies on Risk-sharing in Pharma R&D Collaborations
- Characteristics of Risk-sharing in Pharma R&D Collaborations
- Theoretical Basis for Risk-sharing in Pharma R&D Collaborations
- Managerial Recommendations for Risk-sharing in Pharma R&D Collaborations
- Conclusion.